MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value
$1.10−0.03 (-2.65%)
Close on Nov 11, 2026Market cap $113.53MP/E –Yield –
MaxCyte enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
MaxCyte's enterprise value was $11.06M on Nov 11, 2026, against $81.97M a year earlier. Over the last 5 years it ranged from -$28.02M to $767.53M, with a median of $233.87M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $11.06M | -81.4% |
| 2025 | Dec 31, 2025 | $59.57M | -79.0% |
| 2024 | Dec 31, 2024 | $284.22M | -4.1% |
| 2023 | Dec 29, 2023 | $296.44M | -8.4% |
| 2022 | Dec 30, 2022 | $323.51M | -57.9% |
| 2021 | Dec 31, 2021 | $767.53M | – |
See a number that looks wrong?